{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:23:19Z","timestamp":1787977399317,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd006654","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T00:00:00Z","timestamp":1268784000000}}],"reference-count":282,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006654.pub2","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T11:37:34Z","timestamp":1268739454000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Olanzapine versus other atypical antipsychotics for schizophrenia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Katja","family":"Komossa","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen, Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychosomatische und Medizin und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rummel-Kluge","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie der Universit\u00e4t Leipzig; Semmelweisstr. 10 04103 Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Hunger","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schmid","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Duggan","sequence":"additional","affiliation":[{"name":"Kneeswork House Hosptial; Partnership in Care Bassingbourn Herts UK SG8 5JP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,17]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4088\/JCP.v64n0516","article-title":"Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics","volume":"64","author":"Atmaca","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0002|cit2","first-page":"S473","article-title":"Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study","volume":"15","author":"Bai","year":"2005","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006654.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.v67n0910","article-title":"The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone","volume":"67","author":"Phillips","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0006|cit6","unstructured":"Canive JM Edgar JC LaNoue MD Miller GA Weisend MP Tuason VB A magnetoencephalographic examination on the effects of olanzapine and risperidone in patients with schizophrenia Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30 - Jun 2; Boca Raton, Florida, USA USA 2000"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0007|cit7","first-page":"105","article-title":"Efficacy of olanzapine and risperidone in schizophrenia: A randomized double-blind crossover design","volume":"39","author":"Canive","year":"2000","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0008|cit8","unstructured":"CN138003 A multicenter, double-blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia Clinical Study Report 2005"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0011|cit9","doi-asserted-by":"crossref","unstructured":"Conley RR Mahmoud R A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder American Journal of Psychiatry 2001 765 74","DOI":"10.1176\/appi.ajp.158.5.765"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0012|cit10","unstructured":"Conley RR Mahmoud R Risperidone and olanzapine in people with schizophrenia or schizoaffective disorder: a randomised double-blind study (as supplied 2001) Data on file"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0009|cit11","doi-asserted-by":"crossref","unstructured":"Conley RR Mahmoud R =Risperidone Study Group Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder Proceedings of the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5-11; Davos, Switzerland 2000","DOI":"10.1016\/S0924-977X(00)80433-2"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0010|cit12","first-page":"110","article-title":"Risperidone versus olanzapine in patients with schizophrenia and schizoaffective psychosis","volume":"19","author":"Conley","year":"2000","journal-title":"Nervenheilkunde"},{"issue":"3-4","key":"10.1002\/14651858.CD006654.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00213-002-1342-5","article-title":"Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study","volume":"169","author":"Harvey","year":"2003","journal-title":"Psychopharmacology"},{"issue":"3-4","key":"10.1002\/14651858.CD006654.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/B:ACLI.0000008171.90644.f8","article-title":"Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia","volume":"15","author":"Kelly","year":"2003","journal-title":"Annals of Clinical Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0016|cit15","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/S0924-977X(06)70015-3","article-title":"The treatment of post-psychotic depression","volume":"16","author":"Dollfus","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD006654.pub2-BIB0015|cit16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.schres.2005.06.001","article-title":"Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients","volume":"78","author":"Dollfus","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1, 2","key":"10.1002\/14651858.CD006654.pub2-BIB0017|cit17","first-page":"225","article-title":"A prospective, randomized, doubleblind study examining functioning in schizophrenic patients treated with olanzapine and risperidone","volume":"49","author":"Dolnak","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD006654.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0920-9964(02)00226-8","article-title":"Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand","volume":"61","author":"Gureje","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"9","key":"10.1002\/14651858.CD006654.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/gps.929","article-title":"Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder","volume":"18","author":"Harvey","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006654.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/00019442-200311000-00008","article-title":"International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia","volume":"11","author":"Jeste","year":"2003","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0021|cit21","first-page":"S314","article-title":"Anticholinergic effect of atypical antipsychotics in elderly patients","volume":"12","author":"Tune","year":"2002","journal-title":"European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","article-title":"One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia","volume":"81","author":"Keefe","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/ebmh.9.3.71","article-title":"Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks","volume":"9","author":"Lysaker","year":"2006","journal-title":"Evidence-Based Mental Health"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","article-title":"A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms","volume":"26","author":"Kinon","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.jcp.0000236658.16286.25","article-title":"Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning","volume":"26","author":"Kinon","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0027|cit26","unstructured":"Krakowski MI Clozapine and olanzapine in violent schizophrenics CRISP database (https:\/\/www-commons.cit.nih.gov\/crisp\/index.html"},{"issue":"6","key":"10.1002\/14651858.CD006654.pub2-BIB0026|cit27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","article-title":"Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Krakowski","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0028|cit28","first-page":"1","article-title":"Clozapine and \"high-dose\" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison","volume":"4","author":"Kumra","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD006654.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0032|cit32","unstructured":"Keefe RSE Gu H Sweeney JA Perkins DO McEvoy JP Hamer RM Lieberman JA The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first-episode psychosis: a double-blind 52-week comparison Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0033|cit33","first-page":"S525","article-title":"Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone","volume":"15","author":"Lieberman","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006654.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/S0920-9964(06)70390-5","article-title":"Clinical effectiveness and predictors of treatment non-adherence: comparison of olanzapine, quetiapine, and risperidone in first-episode psychosis","volume":"86","author":"McEvoy","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1016\/S0924-977X(06)70541-7","article-title":"Olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: effectiveness and factors influencing adherence to treatment","volume":"16","author":"McEvoy","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0037|cit37","first-page":"187","article-title":"Long-term weight effects of aripiprazole versus olanzapine","volume":"67","author":"Jody","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0038|cit38","unstructured":"Kujawa MJ McQuade RD Jody DN Carson WH Abou-Gharbia N Iwamoto T Archibald DG Stock EG Long-term weight effects of aripiprazole vs olanzapine in a 26-week, double-blind study Proceedings of the XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20\u201324, Paris, France 2004"},{"issue":"Suppl 18","key":"10.1002\/14651858.CD006654.pub2-BIB0039|cit39","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study","volume":"65","author":"McQuade","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/oxfordjournals.schbul.a007102","article-title":"The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients","volume":"30","author":"Alphs","year":"2004","journal-title":"Schizophrenia Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD006654.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1176\/appi.ajp.161.8.1494","article-title":"Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial","volume":"161","author":"Bourgeois","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4088\/JCP.v65n0513","article-title":"Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior","volume":"65","author":"Glick","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia","volume":"60","author":"Meltzer","year":"2003","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0006-3223(03)00178-1","article-title":"Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial","volume":"54","author":"Potkin","year":"2003","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/026988110401800306","article-title":"Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine","volume":"18","author":"Moresco","year":"2004","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.pnpbp.2004.01.019","article-title":"Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia","volume":"28","author":"Mori","year":"2004","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0048|cit47","unstructured":"Mortimer A The European First Episode Schizophrenia Trial: comparison of outcome in first episode schizophrenia with different low dose antipsychotic regimens (EUFEST) National Research Register 2003"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0047|cit48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004850-200403000-00002","article-title":"A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia","volume":"19","author":"Mortimer","year":"2004","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S1461145705005924","article-title":"Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs clozapine","volume":"9","author":"Bender","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0447.2004.00486.x","article-title":"Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia","volume":"111","author":"Naber","year":"2005","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0051|cit51","first-page":"190","article-title":"The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single-blind trial in patients with schizophrenia","volume":"67","author":"Ozguven","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia","volume":"57","author":"Purdon","year":"2000","journal-title":"Archives of General Psychiatry"},{"issue":"3-4","key":"10.1002\/14651858.CD006654.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00213-003-1505-z","article-title":"Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol","volume":"169","author":"Purdon","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00406-007-0739-x","article-title":"Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia","volume":"748","author":"Riedel","year":"2007","journal-title":"European Archieves of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1176\/ajp.2006.163.12.2096","article-title":"Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcome","volume":"163","author":"Robinson","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0058|cit56","unstructured":"Sacchetti E Valsecchi P Regini C Galluzzo A Cacciani P Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia Proceedings of the Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy 2004"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0056|cit57","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/S0924-977X(03)92114-6","article-title":"Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study","volume":"13","author":"Sacchetti","year":"2003","journal-title":"European College of Neuropsychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0057|cit58","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1016\/S0924-977X(04)80342-0","article-title":"Comparison of quetiapine, olanzapine, and risperidone in schizophrenia","volume":"14","author":"Sacchetti","year":"2004","journal-title":"European College of Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD006654.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":"Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison","volume":"63","author":"Shaw","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0062|cit60","unstructured":"Sikich L Critical decisions in the treatment of adolescent and pediatric psychosis 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0063|cit61","unstructured":"Sikich L Critical decisions in the treatment of adolescent and pediatric psychosis Proceeding of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0060|cit62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropyschopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0061|cit63","unstructured":"Sikich L Williamson K Malekpour A Bashford RA Hooper S Sheitman B Lieberman JA Interim results of a randomized controlled trial of haloperidol, risperidone, and olanzapine in psychotic youth Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico USA 1999"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0064|cit64","unstructured":"Harvey PD Bowie C Loebel AD Long-term cognitive improvement: ziprasidone versus olanzapine Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA 2004"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0924-977X(04)80360-2","article-title":"Cognitive improvement and neuropsychological normalization with ziprasidone or olanzapine: Results of a 6-month study","volume":"14","author":"Harvey","year":"2004","journal-title":"European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00213-003-1652-2","article-title":"Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"172","author":"Harvey","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0067|cit67","unstructured":"Masand PS Loebel AD Analysis of remission in a six-month double-blind continuation study of ziprasidone versus olanzapine Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0068|cit68","unstructured":"Meyer J Nasrallah H Loebel A Parsons B Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6-week randomized study in patients with acute schizophrenia Proceedings of the Collegium Internationale Neuro-Psychopharmacologium 25th Biennial Congress; 2006 July 9-13, Chicago, Illinois 2006"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0069|cit69","unstructured":"Meyer JM Loebel AD Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a six-week randomized study in patients with acute schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"10","key":"10.1002\/14651858.CD006654.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1176\/ajp.161.10.1837","article-title":"Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder","volume":"161","author":"Simpson","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006654.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1176\/appi.ajp.162.8.1535","article-title":"Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia","volume":"162","author":"Simpson","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0074|cit72","unstructured":"Sirota P Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0072|cit73","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/hup.763","article-title":"Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia","volume":"21","author":"Sirota","year":"2006","journal-title":"Human Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0073|cit74","first-page":"170","article-title":"The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia","volume":"67","author":"Sirota","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0924-977X(03)91983-3","article-title":"Olanzapine versus risperidone in first-episode schizophrenic and schizoform disorders: a double-blind comparison","volume":"13","author":"Svestka","year":"2003","journal-title":"European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0924-977X(03)91983-3","article-title":"A double-blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders","volume":"13","author":"Svestka","year":"2003","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0078|cit78","first-page":"4","article-title":"Comparison of olanzapine versus ziprasidone in acute schizophrenia","volume":"9","author":"Svestka","year":"2005","journal-title":"Psychiatrie Prague"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0079|cit79","unstructured":"Beuzen JN Birkett M Kiesler G Wood A Olanzapine vs. clozapine in resistant schizophrenic patients - results of an international double- blind randomised clinical trial Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK 1998"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0081|cit81","unstructured":"Ahmed S Zhang F Walker D Beglinger L Earley WR Tran PV Olanzapine versus risperidone for treatment of negative symptoms in schizophrenia Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006654.pub2-BIB0082|cit82","first-page":"S92","article-title":"Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia","volume":"3","author":"Edgell","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD006654.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"998","DOI":"10.4088\/JCP.v64n0904","article-title":"Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years","volume":"64","author":"Feldman","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00004850-200203000-00004","article-title":"Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders","volume":"17","author":"Glick","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0085|cit85","first-page":"20S","article-title":"Olanzapine versus risperidone in the treatment of psychosis. Preliminary report","volume":"41","author":"Tollefson","year":"1997","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0089|cit87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000091802","article-title":"Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis","volume":"39","author":"Nimwegen","year":"2006","journal-title":"Psychopathology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0087|cit88","unstructured":"Van Nimwegen L De Haan L Van Beveren N Laan W Van De Brink W Linszen D Obsessive compulsive symptoms in a randomized double blind Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 6-10; Davos, Switzerland 2006"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0088|cit89","unstructured":"Van Nimwegen L De Haan L Van Beveren N Laan W Van De Brink W Linszen D Subjective well-being and craving for cannabis in first psychosis, a randomized double blind comparison of olanzapine versus risperidone Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 6-10; Davos, Switzerland 2006"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eurpsy.2006.09.003","article-title":"A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression","volume":"21","author":"Vanelle","year":"2006","journal-title":"European Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S0924-977X(04)80338-9","article-title":"Metabolic control in patients with comorbid schizophrenia and depression treated with amisulpride or olanzapine","volume":"14","author":"Vanelle","year":"2004","journal-title":"European College of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006654.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder","volume":"159","author":"Bilder","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD006654.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1176\/appi.ps.52.11.1510","article-title":"Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia","volume":"52","author":"Citrome","year":"2001","journal-title":"Psychiatric Services"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychotic-induced weight gain and therapeutic response: A differential association","volume":"22","author":"Czobor","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4088\/JCP.v65n0416","article-title":"Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpsychires.2004.04.010","article-title":"Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder","volume":"39","author":"Nolan","year":"2005","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.jcp.0000117424.05703.29","article-title":"Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"24","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Voruganti LP Awad AG Parker G Forrest C Usmani Y Fernando MLD Senthilal S Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine Schizophrenia Research 2007 146 55","DOI":"10.1016\/j.schres.2007.08.002"},{"issue":"6","key":"10.1002\/14651858.CD006654.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.biopsych.2005.07.012","article-title":"Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine","volume":"59","author":"Quednow","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.npp.1300626","article-title":"Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride","volume":"30","author":"Wagner","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0104|cit104","first-page":"143","article-title":"A double-blind randomized controlled study of olanzapine and clozapine on treatment of schizophrenia","volume":"14","author":"Wang","year":"2002","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006654.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jpsychires.2006.03.008","article-title":"Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study","volume":"40","author":"Wang","year":"2006","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0106|cit106","first-page":"1","article-title":"Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial","volume":"5","author":"Wynn","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/S0924-977X(99)80350-2","article-title":"The cost-analysis of olanzapine compared with haloperidol and risperidone in the treatment of schizophrenia in the UK","volume":"9","author":"Almond","year":"1999","journal-title":"European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.jcp.0000222513.63767.de","article-title":"A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia","volume":"26","author":"Alvarez","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD006654.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.4088\/JCP.v67n0812","article-title":"Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial","volume":"67","author":"Alvarez-Jimenez","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0110|cit110","first-page":"474","article-title":"Superior cognitive efficacy of atypical antipsychotics olanzapine, risperidone, and quetiapine, as a group, relative to low doses of conventional antipsychotics","volume":"31","author":"Antonova","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/S1461145703003742","article-title":"Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine","volume":"6","author":"Apiquian","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0112|cit112","unstructured":"Aquila R Weiden PJ Kinon BJ Milton DR Zygmunt A Swindle RW Stauffer VL Effectiveness of olanzapine upon psychiatric and vocational rehabilitation outcomes Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"issue":"8","key":"10.1002\/14651858.CD006654.pub2-BIB0113|cit113","first-page":"1","article-title":"Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia","volume":"6","author":"Ascher-Svanum","year":"2006","journal-title":"BMC Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0114|cit114","first-page":"S403","article-title":"Side effects of atypical antipsychotics - prediction factor for compliance","volume":"16","author":"Baloescu","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006654.pub2-BIB0116|cit116","first-page":"121S","article-title":"Treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo","volume":"49","author":"Beasley","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0920-9964(03)80243-8","article-title":"Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo","volume":"60","author":"Beasley","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD006654.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000095348.32154.ec","article-title":"A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse","volume":"23","author":"Beasley","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1, 2","key":"10.1002\/14651858.CD006654.pub2-BIB0119|cit119","first-page":"220","article-title":"A comparison of patient satisfaction between seroquel, olanzapine and risperidal","volume":"49","author":"Bera","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0120|cit120","unstructured":"Beuzen J-N Pans M Modell S Hagens P McQuade R Iwamoto T Carson W Naturalistic study of aripiprazole treatment Proceedings of the XIII World Congress of Psychiatry; 2005 10-15th Sept; Cairo, Egypt 2005"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-200501000-00004","article-title":"Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients","volume":"20","author":"Bitter","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S0924-977X(04)80317-1","article-title":"The risk of new-onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine","volume":"14","author":"Blonde","year":"2004","journal-title":"European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.npp.1300368","article-title":"Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia","volume":"29","author":"Boylan","year":"2004","journal-title":"Neuropyschopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0920-9964(01)00322-X","article-title":"Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients","volume":"57","author":"Briken","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"36","key":"10.1002\/14651858.CD006654.pub2-BIB0125|cit125","first-page":"63","article-title":"Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia","volume":"9","author":"Cao","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0126|cit126","unstructured":"Casey D L'Italien G Waldeck R Cislo P Carson W Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17\u201322; San Francisco, California, USA 2003"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/S0924-977X(06)70201-2","article-title":"Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels","volume":"16","author":"Chaudhry","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0128|cit128","first-page":"298","article-title":"A control study of elderly patients with schizophrenia treated with olanzapine or clozapine","volume":"13","author":"Chen","year":"2003","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0129|cit129","first-page":"217","article-title":"A controlled study of olanzapine versus clozapine in schizophrenia","volume":"11","author":"Chen","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","article-title":"Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine","volume":"189","author":"Chrzanowski","year":"2006","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ps.55.3.290","article-title":"Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone","volume":"55","author":"Citrome","year":"2004","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0132|cit132","unstructured":"Ciudad A \u00c1lvarez E Bouso\u00f1o M Cuesta M G\u00f3mez JC Olivares JM Olanzapine versus risperidone: Results of a one-year randomized trial in outpatients with schizophrenia with prominent negative symptoms Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-14; Davos, Switzerland 2004"},{"issue":"1-3","key":"10.1002\/14651858.CD006654.pub2-BIB0133|cit133","first-page":"128","article-title":"A comparison of the neurocognitive effects of treatment with typical and atypical neuroleptics in first-episode schizophrenia","volume":"36","author":"Conley","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006654.pub2-BIB0134|cit134","first-page":"S185","article-title":"Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis","volume":"5","author":"Cornblatt","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD006654.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4088\/JCP.v67n1004","article-title":"A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis","volume":"67","author":"Crespo-Facorro","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4088\/JCP.v62n0310","article-title":"Analysis of the qtc interval during olanzapine treatment of patients with schizophrenia and related psychosis","volume":"62","author":"Czekalla","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0137|cit137","first-page":"291","article-title":"Comparative study on the effect of olanzapine and seroquel of schizophrenia","volume":"13","author":"Dai","year":"2004","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0138|cit138","first-page":"396","article-title":"Comparative study on the influence of olanzapine and clozapine on efficacy and quality of life in schizophrenia","volume":"13","author":"Dai","year":"2004","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00213-005-0117-1","article-title":"Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia","volume":"182","author":"Dakhale","year":"2005","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD006654.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006654.pub2-BIB0141|cit141","first-page":"s140","article-title":"Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents","volume":"3","author":"David","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4088\/JCP.v63n0203","article-title":"Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders","volume":"63","author":"Haan","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0143|cit143","first-page":"143","article-title":"A comparative trial of olanzapine versus clozapine in the treatment of schizophrenia","volume":"12","author":"Deng","year":"2000","journal-title":"Shanghai Archives of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4088\/JCP.v66n0810","article-title":"Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study","volume":"66","author":"Dossenbach","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.1016\/S0924-977X(06)70505-3","article-title":"Genetic predictors of cognitive function and response to treatment in schizophrenia","volume":"16","author":"Ertugrul","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD006654.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","article-title":"The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial","volume":"78","author":"Fleischhacker","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1016\/S0924-977X(06)70455-2","article-title":"Sexual side effects of antipsychoticcs and treatment adherence","volume":"16","author":"Garc\u00eda","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1017\/S0033291799002639","article-title":"Effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning","volume":"30","author":"Goldberg","year":"2000","journal-title":"Psychological Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0150|cit150","unstructured":"Harrison D Leaderer M Loebel A Murray S Ziprasidone vs. olanzapine: change in coronary heart disease risk during a 6-week trial Proceedings of the thematic conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy 2004"},{"issue":"6","key":"10.1002\/14651858.CD006654.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"Heresco-Levy","year":"2005","journal-title":"Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006654.pub2-BIB0152|cit152","first-page":"343","article-title":"Czech results of the RODOS study: comparison of risperidone and olanzapine from the point of view of efficacy, tolerability and treatment costs","volume":"97","author":"Hrdlicka","year":"2001","journal-title":"Ceska A Slovensk\u00e1 Psychiatrie"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1600-0447.2003.00251.x","article-title":"Psychotic disorders and gonadal function: Evidence supporting the oestrogen hypothesis","volume":"109","author":"Huber","year":"2004","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1052-z","article-title":"Subjective well-being and quality of life under atypical antipsychotic treatment","volume":"162","author":"Karow","year":"2002","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13651500600579068","article-title":"Clinical experience with atypical antipsychotics in an acute inpatient unit: Focus on quetiapine","volume":"10","author":"Keks","year":"2006","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0924-977X(06)70549-1","article-title":"Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?","volume":"16","author":"Kelemen","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","article-title":"The neurocognitive effects of aripriprazole: an open-label comparison with olanzapine","volume":"187","author":"Kern","year":"2006","journal-title":"Psychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1016\/S0924-977X(04)80250-5","article-title":"The comparison of risperidone, olanzapine and quetiapine in the treatment of chronic schizophrenia and schizoaffective disorder","volume":"14","author":"Kim","year":"2004","journal-title":"European College of Neuropsychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006654.pub2-BIB0159|cit159","first-page":"17","article-title":"Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006654.pub2-BIB0160|cit160","first-page":"S59","article-title":"Differential effects of antipsychotic drugs on clinical symptoms and cognitive functions in the treatment of schizophrenia","volume":"10","author":"Kolff","year":"2000","journal-title":"European College of Neuropsychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD006654.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/BF03040274","article-title":"Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia","volume":"115","author":"Kores Plesnicar","year":"2003","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0162|cit162","unstructured":"Kropp S Grohmann R Hauser U R\u00fcther E Degner D Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project Pharmacopsychiatry 2004"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/j.1440-1614.2006.01820.x","article-title":"Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia","volume":"40","author":"Lee","year":"2006","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006654.pub2-BIB0164|cit164","first-page":"37","article-title":"A controlled study of olanzapine and risperidol in the treatment of elderly patients with schizophrenia","volume":"16","author":"Lin","year":"2005","journal-title":"Hainan Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/01.jcp.0000167791.70664.d4","article-title":"Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments","volume":"25","author":"Lipkovich","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0166|cit166","unstructured":"Littrell KH Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open-label randomized trial Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA 1999"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0167|cit167","first-page":"282","article-title":"A controlled study on olanzapine and clozapine in the treatment of the acute phase of schizophrenia","volume":"16","author":"Liu","year":"2004","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0168|cit168","first-page":"S522","article-title":"Hyperprolactinemia during schizophrenia treatment with atypical antipsychotics: oral risperidone, depot risperidone, and oral olanzapine","volume":"15","author":"Loza","year":"2005","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.psychres.2004.07.008","article-title":"A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition","volume":"129","author":"Malla","year":"2004","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/S0924-977X(99)80369-1","article-title":"Comparative assessment of the positive and negative symptom dynamics in schizophrenic patients treated with atypical antipsychotics or haloperidol","volume":"9","author":"Malyarov","year":"1999","journal-title":"European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0924-977X(03)92108-0","article-title":"Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia","volume":"13","author":"Mazurek","year":"2003","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0172|cit172","unstructured":"Meltzer HY Gilliam JH Nasdahl C Olanzapine causes greater increases in serum lipids than risperidone Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00004850-200201000-00007","article-title":"Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication","volume":"17","author":"Moritz","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0174|cit174","unstructured":"Mortimer A Randomised prospective parallel group comparison of clozapine vs olanzapine in the reduction of suicidality in patients with schizophrenia\/schizoaffective disorder National Research Register 2002"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1016\/S0924-977X(06)70522-3","article-title":"SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics","volume":"16","author":"Musil","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00166-3","article-title":"Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs","volume":"50","author":"Naber","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00001504-200201000-00006","article-title":"Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration","volume":"15","author":"Naber","year":"2002","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0178|cit178","unstructured":"Newcomer JW L'Italien G Vester-Blockland McQuade RD Carson WH Marcus RN Improvement of non-hdl cholesterol levels among patients randomized to aripiprazole versus olanzapine Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0920-9964(00)90755-2","article-title":"Is olanzapine a substitute for clozapine? The effects on psychomotor performance","volume":"41","author":"Oliemeulen","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0180|cit180","unstructured":"Opjordsmoen S Brunsvik S Melle I Dahl A Friis S Haahr U Hustoft K Johannessen JO Larsen TK McGlashan TH Simonsen E Vaglum P A comparison between novel and traditional antipsychotics as first-line medication in early psychosis Proceedings of the 2nd International Conference on Early Psychosis; 2000 Mar 31 - Apr 2; New York, New York, USA 2000"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0181|cit181","unstructured":"Ortega-Soto H Apiquian R Ulloa RE Salas M Loyzaga C Mendizabal A Brunner E Olanzapine vs risperidone. A double blind trial in Mexican patients Proceedings of the Collegium Internationale Neuro-Psychopharmacologicum Regional Meeting; 1997 Aug 21-23; Acapulco, Mexico 1997"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0182|cit182","first-page":"32","article-title":"A study of olanzapine and clozapine in treatment of schizophrenia","volume":"16","author":"Pan","year":"2006","journal-title":"Zhejiang Journal of Integrated Traditional Chinese and Western Medicine"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0183|cit183","doi-asserted-by":"crossref","unstructured":"Perro C Naber D Lambert M Moritz S Krause M A prospective clinical comparative-study of four atypical antipsychotic agents in the treatment of schizophrenia Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 13","DOI":"10.2165\/00128413-199912110-00012"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/S0924-977X(04)80235-9","article-title":"Medication-specific correlates of relapse risk in schizophrenia","volume":"14","author":"Peuskens","year":"2004","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0185|cit185","unstructured":"Rabinowitz J Pattern mixture approach to comparing outcomes - of benefit in guideline development Proceedings of the 18th European College of Neuropsychopharmacology Congress; 2005 October 22-26, Amsterdam, Netherlands 2005"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006654.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1016\/S0924-977X(04)80327-4","article-title":"An economic evaluation of aripiprazole compared to olanzapine based on metabolic side-effect profile","volume":"14","author":"Ray","year":"2004","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0187|cit187","unstructured":"Reznik I Slavkin L Shabash E Shaked G Kertzman S Spivak B Weizman A Kotler M Quetiapine ('Seroquel') and olanzapine for acute treatment of patients with schizophrenia: an open-label, comparative study Proceedings of the XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20\u201324, Paris, France France 2004 1 4"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0188|cit188","unstructured":"Roerig JL Mitchell JE de Zwaan M Crosby RD Gosnell BA Pederson K A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors and ghrelin plasma levels in normal human subjects Proceedings of the thematic conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy 2004"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/S0924-977X(06)70530-2","article-title":"Association of leptin gene polymorphism with antipsychotic drug-induced weight gain","volume":"16","author":"Ryu","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0190|cit190","unstructured":"Sanchez R Kostic D Stock E Torbeyns AF Kerselaers W Nyilas M McQuade R Carson WH Marcus RN Aripiprazole vs olanzapine in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week open-label extension study Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 February 4-10, Davos, Switzerland 2006"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00213-003-1506-y","article-title":"Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia","volume":"169","author":"Sharma","year":"2003","journal-title":"Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006654.pub2-BIB0192|cit192","first-page":"S170","article-title":"Antipsychotics and diabetes: lack of evidence for a causal relationship","volume":"5","author":"Sowell","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00213-005-0205-2","article-title":"A crossover study on lipid and weight changes associated with olanzapine and risperidone","volume":"183","author":"Su","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0194|cit194","unstructured":"Swanson JW Swartz MS Van Dorn RA Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/S0924-977X(06)70490-4","article-title":"Olanzapine versus ziprasidone in parenteral administration in psychotic relapse of schizophrenia","volume":"16","author":"Tudor","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1524-4733.2006.00083.x","article-title":"Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial","volume":"9","author":"Tunis","year":"2006","journal-title":"Value in Health"},{"issue":"6","key":"10.1002\/14651858.CD006654.pub2-BIB0197|cit197","first-page":"341","article-title":"Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia","volume":"18","author":"Bruggen","year":"2003","journal-title":"International Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/j.1440-1614.2000.00813.x","article-title":"Community treatment orders: Relationship to clinical care, medication compliance, behavioural disturbance and readmission","volume":"34","author":"Vaughan","year":"2000","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"03","key":"10.1002\/14651858.CD006654.pub2-BIB0199|cit199","first-page":"141","article-title":"A study of olanzapine and clozapine in the treatment of schizophrenia.","volume":"16","author":"Wang","year":"2003","journal-title":"Shandong Archires of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006654.pub2-BIB0200|cit200","first-page":"9","article-title":"Comparison of efficacy safety of olanzapine and risperidone in the treatment of first episode schizophrenia","volume":"10","author":"Wang","year":"2004","journal-title":"International Medicine and Health Guidance News"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0201|cit201","first-page":"289","article-title":"Controlled study of the effect of olanzapine and clozapine on electroencephalogram of schizophrenic patients","volume":"6","author":"Wang","year":"2004","journal-title":"Journal of North China Coal Medical College"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0202|cit202","first-page":"224","article-title":"Effectiveness of olanzapine in treatment of schizophrenia","volume":"15","author":"Wang","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006654.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/sj.npp.1300216","article-title":"Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds","volume":"28","author":"Weickert","year":"2003","journal-title":"Neuropyschopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0204|cit204","unstructured":"Wolf K Wolf K Mass R Kiefer F Wiedemann K Naber D Improvement of facial expression of emotions (fee) of schizophrenic patients under olanzapine versus risperidone. A prospective facial-emg study Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.jcp.0000165739.55142.23","article-title":"The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia-preliminary results of a facial electromyogram study","volume":"25","author":"Wolf","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00213-006-0384-5","article-title":"Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"186","author":"Wu","year":"2006","journal-title":"Psychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006654.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1016\/S0924-977X(06)70447-3","article-title":"Vitamin D deficiency and impaired parathormone metabolism as a risk factor of low bone mineral density in patients with diagnosis of schizophrenia treated with second generation antipsychotics","volume":"16","author":"Wyszogrodzka-Kucharska","year":"2006","journal-title":"European College of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006654.pub2-BIB0208|cit208","first-page":"S135","article-title":"Depressive symptoms under atypical neuroleptic treatment in schizophrenia","volume":"71","author":"Yagdiran","year":"2000","journal-title":"Nervenarzt"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00019442-200505000-00006","article-title":"Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults","volume":"13","author":"Yamashita","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006654.pub2-BIB0210|cit210","first-page":"338","article-title":"A comparison of olanzapine and risperidone in the treatment of first-episode schizophrenia","volume":"15","author":"Yang","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006654.pub2-BIB0211|cit211","first-page":"177","article-title":"An economic burden comparison of typical and atypical antipsychotic therapies for schizophrenia","volume":"35","author":"Yu","year":"2002","journal-title":"Chinese Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0212|cit212","unstructured":"Zelaschi Sr NM Rodriguez Sr JL Gaitan Sr S Palacios Vallejos Sr ME Zieher Sr LM The effects of the switch of conventional neuroleptics to atypical antipsychotics: a follow-up study of patients with chronic schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"14","key":"10.1002\/14651858.CD006654.pub2-BIB0213|cit213","first-page":"113","article-title":"A study of olanzapine and clozapine in EEG","volume":"10","author":"Zhang","year":"2004","journal-title":"International Medicine and Health Guidance News"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0214|cit214","first-page":"865","article-title":"A clinical study of clozapine and olanzapine in treatment of resistant schizophrenia","volume":"22","author":"Zheng","year":"2001","journal-title":"Journal of Qiqihar Medical College"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0215|cit215","first-page":"30","article-title":"Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia","volume":"10","author":"Zhong","year":"2006","journal-title":"Zhongguo Linchuang Kangfu"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1043-6618(03)00178-6","article-title":"Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia","volume":"48","author":"Zoccali","year":"2003","journal-title":"Pharmacological Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0217|cit217","unstructured":"Eli Lilly Company Study of olanzapine vs aripiprazole in the treatment of schizophrenia Eli Lilly and Company Clinical Trial Registry 2003"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0218|cit218","unstructured":"Eli Lilly Company Safety study of olanzapine and a comparator in patients with schizophrenia and schizoaffective disorder Eli Lilly and Company Clinical Trial Registry 2003"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0219|cit219","unstructured":"Eli Lilly Company Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia Eli Lilly and Company Clinical Trial Registry 2004"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0220|cit220","unstructured":"Eli Lilly Company Comparison of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder Eli Lilly and Company Clinical Trial Registry 2004"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0221|cit221","unstructured":"Eli Lilly Company Efficacy study of early onset of antipsychotic drug action in schizophrenia Eli Lilly and Company Clinical Trial Registry 2006"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0222|cit222","unstructured":"Mortimer A A1281014 a phase IIIb, 12 week, multi-centre, double-blind, double-dummy, randomised, parallel group study comparing the effects of ziprasidone versus olanzapine on quality of life in the treatment of schizophrenia and schizoaffective disorder National Research Register 2001"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0223|cit223","unstructured":"Reveley M Ris-int-45 an international, multicentre, randomised double-blind parallel-group trial comparing the safety and efficacy of risperidone and olanzapine in the treatment of patients with schizophrenia National Research Register 2000"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0224|cit224","unstructured":"Reveley M MREC\/00\/1\/47 a phase IIIb multicentre randomised double-blind trial of ziprasidone vs olanzapine in schizophrenia National Research Register 2003"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0225|cit225","unstructured":"Magnuson WG Childhood onset psychotic disorders:characterization and treatment with atypical neuroleptics \/ Treatment of childhood onset psychotic disorders with olanzapine or clozapine National Institutes of Health 2001"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecing skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0227|cit227","volume-title":"Scale for the assessment of negative symptoms (SANS)","author":"Andeasen","year":"1983"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0228|cit228","volume-title":"Scale for the assessment of positive symptoms (SAPS)","author":"Andreasen","year":"1984"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0229|cit229","first-page":"11","article-title":"Olanzapine, sertindole and schizophrenia","volume":"35","author":"Anonymous","year":"1997","journal-title":"Drugs and Therapeutics Bulletin"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0230|cit230","first-page":"1","volume-title":"Practice guidelines for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2004"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0234|cit234","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrom","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0237|cit237","first-page":"233","article-title":"The extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/ajp.155.7.914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistent schizophrenia","volume":"155","author":"Conley","year":"1998","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0239|cit239","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0242|cit242","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0244|cit244","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006654.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0246|cit246","first-page":"222","article-title":"The Hillside Akathisia Skale: a new rating instrument for neuroleptic-induced akathisia","volume":"25","author":"Fleischhacker","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0248|cit248","unstructured":"Gaebel W Falkai P Weinmann S Wobrock T Treatment guidelines for schizophrenia Steinkopf 2006"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.149.9.1148","article-title":"Revising axis V for DSM-IV: a review of measures of social functioning","volume":"149","author":"Goldman","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0251|cit251","doi-asserted-by":"crossref","unstructured":"Guy U ECDEU assessment manual for psychopharmacology. Revised. National Institute of MentalHealth 1976","DOI":"10.1037\/e591322011-001"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0254|cit254","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"2","key":"10.1002\/14651858.CD006654.pub2-BIB0255|cit255","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005237.pub2","article-title":"Risperidone versus olanzapine for schizophrenia.","author":"Jayaram","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0258|cit258","first-page":"585","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"46","author":"Kane","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0259|cit259","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"17","key":"10.1002\/14651858.CD006654.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"iii-iv, ix-xi,","DOI":"10.3310\/hta10170","article-title":"Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment","volume":"10","author":"Lewis","year":"2006","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Liebermann","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment - a review","volume":"39","author":"Marvaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT Statement: Revised recommendations for improving the quality of reports of parrallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0267|cit267","first-page":"329","article-title":"New assessment of atypical antipsychotics","volume":"71","author":"M\u00f6ller","year":"2000","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(97)22018-0","article-title":"Olanzapine: a novel atypical neuroleptic agent","volume":"349","author":"Reus","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia","volume":"337","author":"Rosenheck","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0271|cit271","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.156.11.1744","article-title":"Double-blind study of clozapine dose response in chronic schizophrenia","volume":"156","author":"Simpson","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \"Just the Facts\" What we know in 2008. 2. Epidemiology and etiology","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophrenia research"},{"issue":"4","key":"10.1002\/14651858.CD006654.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorder: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006654.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-0447.2005.00659.x","article-title":"Standardized remission criteria in schizophrenia","volume":"113","author":"Os","year":"2006","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130100711","article-title":"Drop-out rates in randomised antipsychotic drug trials","volume":"155","author":"Wahlbeck","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0280|cit280","volume-title":"The World Health report 2001-Mental Health: New understanding, new hope","author":"WHO","year":"2001"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0281|cit281","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo 2007"},{"key":"10.1002\/14651858.CD006654.pub2-BIB0282|cit282","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"American Journal of Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006654.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:07:48Z","timestamp":1738541268000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006654.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,3,17]]},"references-count":282,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006654.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,17]]}}}